Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19671849.
- Also identified by DOI 10.1158/1078-0432.CCR-09-1173.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gain-of-function mutations in the catalytic subunit of phosphoinositide-3-kinase (PI3KCA) occur frequently in breast cancer. Kalinsky and colleagues show that PI3KCA mutations are associated with favorable clinicopathologic features and better clinical outcome, including survival. These findings will have to be considered in the design and interpretation of clinical trials with inhibitors of the PI3K pathway.
Medical subject headings
- Breast Neoplasms
- Mutation
- Phosphatidylinositol 3-Kinases